E-MED: R�sultat du 3�me tour du Fonds Mondial
---------------------------------------------------------------------
[Mod�rateur: vous trouverez ci-dessous la derni�re lettre du Fonds Mondial
pour le Sida, le Paludisme et la tuberculose avec la liste des pays dont les
projets ont �t� accept�s pour ce 3�me tour.CB]
GLOBAL FUND OBSERVER (GFO) NEWSLETTER
A service of Aidspan.
Issue 13 � Sunday 19 October 2003.
Note: For formatted web, Word and PDF versions of this and other issues, see
www.aidspan.org/gfo/archives/newsletter
+ + + + + + + + + + + + + + + + + + +
CONTENTS
+ + + + + + + + + + + + + + + + + + +
* NEWS: Global Fund Approves Third Round of Grants, and Prepares for Round 4
The board has approved Round 3 grants with a 2-year cost of $623 million,
significantly less than expected. Round 4 will be launched on 10 January
2004.
* COMMENTARY: The Need for Technical Assistance
The evidence of Round 3 suggests that the technical merit of proposals being
submitted to the Fund is not increasing, and quite possibly is decreasing.
The Fund could usefully do more in encouraging other institutions to offer
technical assistance to countries that wish to obtain Global Fund financing.
* ANALYSIS: Round Three Decisions
A list is provided showing all eligible applications received in Round 3,
with the board's decision in each case. Also shown are countries that were
eligible to apply but did not do so.
+ + + + + + + + + + + + + + + + + + +
NEWS: Global Fund Approves Third Round of Grants, and Prepares for Round 4
+ + + + + + + + + + + + + + + + + + +
At its board meeting in Chiang Mai, Thailand, on October 15-17, the Global
Fund board approved 71 grants that will cost $623 million over the first two
years. (For a complete list of approved and rejected proposals, see
"Analysis: Round Three Decisions," below.)
The cost of the approved grants was significantly less than had been
expected, and was 30% less than in Round 2. This was for three reasons:
fewer proposals than expected were submitted; most of these were modest in
size; and a smaller percentage than expected were approved.
The board meeting also agreed that Round 4 will be launched on 10 January
2004, with applications to be submitted by about the end of March and
approvals to be made at the board meeting in June. It appears likely that
Round 4 will be the only Round in 2004, and it is far from certain that
there will be any new Round in 2005, because first priority that year will
go to renewing Round 1 and 2 grants.
The board meeting in Chiang Mai went fairly smoothly. Many participants,
including from NGOs and developing countries, praised the way in which
Chairman Tommy Thompson ran the meeting fairly and efficiently.
The Fund issued the following press release on 16 October:
GLOBAL FUND COMMITS US$623 MILLION TO NEW GRANTS TO FIGHT AIDS, TB AND
MALARIA
Chiang Mai � Meeting in Thailand, the Board of the Global Fund to Fight
AIDS, Tuberculosis and Malaria approved $623 million in new two-year grants
to programs fighting the three diseases. This brings the total amount
approved by the Board after three proposal rounds to US$2.1 billion to 125
countries.
"In less than two years the Global Fund has become a leading force in the
fight against these three deadly diseases," said Tommy G. Thompson, United
States Secretary of Health and Human Services and Chair of the Global Fund's
Board. "Working with its partners, the Global Fund is beginning to realize
our commitment to prevention and treatment at a global scale."
To cover the amount recommended for the third round of proposals, the Board
committed to fully funding the round by deferring until January 2004 formal
confirmation of a portion of proposals totaling $138 million out of the
US$623 million. Almost all proposals require additional technical
clarifications before funds are legally obligated.
In addition, the Board agreed to consider a fourth round of proposals for
approval at its meeting in June 2004, with guidelines and proposal forms to
be issued in January.
At the Board Meeting, people living with HIV and international partners,
including the World Health Organization and UNAIDS, affirmed the health
emergency arising from inadequate treatment of HIV. Donors and recipients
affirmed the need to make new commitments quickly and agreed on a calendar
for the next round.
"At this meeting, Members of the Board worked together towards a common
vision of the Global Fund as a major instrument in the world's fight against
these diseases," said Dr Richard Feachem, the Global Fund's Executive
Director. "Their concerns challenge us to do our work better, and to do more
to help the millions in need of support. Agreement by the Board on fully
funding Round 3 and quickly launching Round 4 is an important step forward."
About 60% of the funds approved are targeted at HIV/AIDS, and about the same
are destined for Africa. In total, 57% will be awarded to non-governmental
partners, who work with governments as part of public-private partnerships
called Country Coordinating Mechanisms that develop and submit proposals to
the Global Fund. Over the lifetime of the programs (two years with the
possibility of renewals for another three years based on performance), they
will increase the number of people living with HIV on antiretrovirals by
nearly 200,000 and allow for nearly 7 million people to access HIV voluntary
counseling and testing services. 18 million insecticide-treated nets to
prevent malaria transmission will be purchased with the latest approved
funds, and 760,000 treatments will be provided for tuberculosis.
In aggregate, the US$2.1 billion committed by the Global Fund to date is
characterized as follows, with additional information available on the
website:
By region: 60% Africa; 20% Asia, Middle East and North Africa; 11% Latin
America and the Caribbean; and 9% Eastern Europe.
By disease: 60% HIV/AIDS; 23% malaria; and 17% tuberculosis (with some funds
to joint disease proposals).
By expenditure target: 46% drugs & commodities; 25% human resources and
training; 15 physical infrastructure; 5% monitoring & evaluation; 4%
administrative costs; and 5% other.
By recipient: 50% government; 29% non-governmental and community-based
organizations; 5% private sector; 4% faith-based organizations; 3% people
living with the diseases; 3% academic institutions; 6% other.